文献速递胸部肿瘤头颈与中枢神经肿瘤

卡瑞利珠单抗对比安慰剂联合化疗±放疗一线治疗非小细胞肺癌脑转移:CTONG 2003随机安慰剂对照试验

First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial.
PubMed 文献 · J Thorac Oncol · 2025-02-08

CTONG 2003是多中心随机双盲安慰剂对照试验,针对EGFR/ALK阴性初治NSCLC脑转移患者,1:1随机接受卡瑞利珠单抗或安慰剂联合含铂双药化疗4-6周期,后续维持治疗±培美曲塞至多31周期,必要时42天内放疗。因全球治疗格局变化提前终止,实际入组60例(卡瑞利珠单抗组32例,安慰剂组28例)。卡瑞利珠单抗组中位颅内无进展生存期12.7个月 vs 安慰剂组9.9个月(HR=0.45,95%CI 0.21-0.96),中位无进展生存期9.7个月 vs 6.7个月(HR=0.57,95%CI 0.29-1.11),3级及以上治疗相关不良事件发生率65.6% vs 46.4%。

要点

  • 卡瑞利珠单抗组中位颅内无进展生存期12.7个月,安慰剂组9.9个月,HR=0.45(95%CI 0.21-0.96)。
  • 卡瑞利珠单抗组中位无进展生存期9.7个月,安慰剂组6.7个月,HR=0.57(95%CI 0.29-1.11)。
  • 3级及以上治疗相关不良事件发生率卡瑞利珠单抗组65.6%,安慰剂组46.4%,主要为中性粒细胞计数降低和贫血。

核心结论

  • 尽管试验提前终止,卡瑞利珠单抗在NSCLC脑转移中显示出颅内无进展生存期和无进展生存期改善的趋势,安全性可接受。

研究设计与样本

  • CTONG 2003为多中心、随机、双盲、安慰剂对照试验,纳入EGFR突变和ALK融合阴性的初治NSCLC脑转移患者。
  • 患者按1:1随机接受卡瑞利珠单抗或安慰剂联合含铂双药化疗4-6周期,后续卡瑞利珠单抗或安慰剂±培美曲塞维持治疗至多31周期。
  • 必要时在首次治疗给药后42天内对脑转移灶进行放疗。
  • 共同主要终点为颅内无进展生存期和无进展生存期,计划入组200例,因全球治疗格局变化提前终止招募。
  • 2021年5月28日至2023年7月21日共随机60例,卡瑞利珠单抗组32例,安慰剂组28例。

主要发现

  • 卡瑞利珠单抗组中位颅内无进展生存期为12.7个月(95%CI 7.1-25.3),安慰剂组为9.9个月(95%CI 6.3-14.6),HR=0.45(95%CI 0.21-0.96)。
  • 卡瑞利珠单抗组中位无进展生存期为9.7个月(95%CI 6.6-14.0),安慰剂组为6.7个月(95%CI 4.1-8.6),HR=0.57(95%CI 0.29-1.11)。
  • 3级及以上治疗相关不良事件发生率卡瑞利珠单抗组为65.6%,安慰剂组为46.4%,主要为中性粒细胞计数降低和贫血。

局限性

  • 因全球治疗格局变化,招募提前终止,实际入组60例,低于计划入组200例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Retrospective studies have indicated the potential benefits of immunotherapy for brain metastases (BMs) in NSCLC. To our knowledge, CTONG 2003 is the first randomized controlled trial to evaluate camrelizumab for untreated BM of NSCLC. METHODS: CTONG 2003 is a multicenter, randomized, double-blind, placebo-controlled trial. Treatment-naïve NSCLC with BM, negative for EGFR mutations and ALK fusions, were randomized 1:1 to receive either camrelizumab or placebo, plus platinum-doublet chemotherapy for four to six cycles, followed by maintenance therapy with camrelizumab or placebo with or without pemetrexed for up to 31 cycles. Radiotherapy was administered for BM, if necessary, within 42 days of the first treatment dose. The co-primary endpoints were intracranial progression-free survival (iPFS) and progression-free survival (PFS). The planned enrollment included 200 patients, but recruitment was terminated early because of therapeutic paradigm shifts globally. RESULTS: Between May 28, 2021, and July 21, 2023, 60 patients were randomized, with 32 assigned to the camrelizumab group and 28 to the placebo group. The median iPFS was 12.7 months (95% confidence interval [CI]: 7.1-25.3) for camrelizumab versus 9.9 months (95% CI: 6.3-14.6) for placebo (hazard ratio = 0.45, 95% CI: 0.21-0.96). The median PFS was 9.7 months (95% CI: 6.6-14.0) for camrelizumab versus 6.7 months (95% CI: 4.1-8.6) for placebo (hazard ratio = 0.57, 95% CI: 0.29-1.11). Grade 3 or higher treatment-related adverse events occurred in 65.6% and 46.4% of the respective groups, mainly neutrophil count decrease and anemia. CONCLUSIONS: Despite early termination, camrelizumab demonstrated a trend toward improved iPFS and PFS in the BM of NSCLC with an acceptable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04768075.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Li YS, Yu Q, Bu Q, et al. First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial. J Thorac Oncol. 2025. PMID: 39929333. doi:10.1016/j.jtho.2025.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。